Connect with us

Hi, what are you looking for?

Jewish Business News


XTL Bio returns to Nasdaq

XTL’s lead product is a treatment of multiple myeloma, and it is readying a clinical trial for the product.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.


/ By Gali Weinreb / 

XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB); TASE:XTL) will resume trading on Nasdaq this week, after Nasdaq approved the company’s listing application last week. XTL’s ADR will be traded at a ratio of 20 shares representing each ADR.
XTL had been listed on Nasdaq, as well as the Tel Aviv Stock Exchange (TASE) and London Stock Exchange, until the collapse of its share price following the failure of the clinical trial of its lead product. The company delisted from London, and was relegated to the Pink Sheets on Wall Street.
Two years ago, XTL changed hands, replaced its management, and entered a new business. It has now reached a market cap and capital to return to Nasdaq. Its lead product is recombinant erythropoietin (rHuEPO) for the treatment of multiple myeloma, and it is readying a clinical trial for the product.
Published by 



You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.